Chemomab Therapeutics Ltd. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Chemomab Therapeutics Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Chemomab Therapeutics Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.63M, a 54.4% increase year-over-year.
  • Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$24.2M, a 12.4% increase from 2022.
  • Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$27.6M, a 122% decline from 2021.
  • Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$12.5M, a 110% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$24.2M +$3.43M +12.4% Jan 1, 2023 Dec 31, 2023 20-F 2024-03-28
2022 -$27.6M -$15.2M -122% Jan 1, 2022 Dec 31, 2022 20-F 2024-03-28
2021 -$12.5M -$6.53M -110% Jan 1, 2021 Dec 31, 2021 20-F 2024-03-28
2020 -$5.95M +$21.2M +78.1% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
2019 -$27.1M -$13.3M -96.6% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 -$13.8M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.